Supplementary appendix: The anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenitate in asthma. (DOCX 97 kb
Appendix A Clinical Investigations. Appendix B Lung Function Test. Appendix C Biobank Samples. (DOCX...
Effects of Dexamethasone, PIK-294 and tofacinib on IL-6 from TCR-stimulated BAL cells. BAL cells fro...
Additional file 1: Figure S1. Funnel plot. A, the total effective rate. B, cough recurrence rate. C,...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment ef...
Plot of serious pneumonia incidence per 1000 patient-years and 95% CI by treatment group (integrated...
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
AEs reported by âĽ3 patients in the Japan+Korea cohort of any relevant treatment arm and the corres...
Comparison of % inhibition of IFNγ, IL-13 and IL-17 for dexamethasone, tofacitinib and PIK-294. BAL ...
Study design Figure. Abbreviations: BDI, Baseline Dyspnoea Index; CAT, COPD Assessment Test; FP/SAL,...
Consolidated Standards of Reporting Trials (CONSORT) 2010 checklist of information to include when r...
Online supplement. Online supplement containing additional details regarding COPD medications, treat...
Appendix A Clinical Investigations. Appendix B Lung Function Test. Appendix C Biobank Samples. (DOCX...
Effects of Dexamethasone, PIK-294 and tofacinib on IL-6 from TCR-stimulated BAL cells. BAL cells fro...
Additional file 1: Figure S1. Funnel plot. A, the total effective rate. B, cough recurrence rate. C,...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment ef...
Plot of serious pneumonia incidence per 1000 patient-years and 95% CI by treatment group (integrated...
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
AEs reported by âĽ3 patients in the Japan+Korea cohort of any relevant treatment arm and the corres...
Comparison of % inhibition of IFNγ, IL-13 and IL-17 for dexamethasone, tofacitinib and PIK-294. BAL ...
Study design Figure. Abbreviations: BDI, Baseline Dyspnoea Index; CAT, COPD Assessment Test; FP/SAL,...
Consolidated Standards of Reporting Trials (CONSORT) 2010 checklist of information to include when r...
Online supplement. Online supplement containing additional details regarding COPD medications, treat...
Appendix A Clinical Investigations. Appendix B Lung Function Test. Appendix C Biobank Samples. (DOCX...
Effects of Dexamethasone, PIK-294 and tofacinib on IL-6 from TCR-stimulated BAL cells. BAL cells fro...
Additional file 1: Figure S1. Funnel plot. A, the total effective rate. B, cough recurrence rate. C,...